This is a news story, published by USA Today, that relates primarily to Zepbound news.
For more Zepbound news, you can click here:
more Zepbound newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from USA Today, you can click here:
more news from USA TodayOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
loss medicine Zepbound. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest prescription news, FDA news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
signature weight loss drugUSA Today
•
75% Informative
Eli Lilly sues over knockoffs of its popular weight-loss drug, Zepbound .
FDA took the drug off its list of medicines in short supply earlier this month .
FDA to date has only approved tirzepatide as an injectable drug.
FDA agreed to reconsider a decision last month to bar drug compounders from selling their versions of Eli Lilly's drugs.
VR Score
70
Informative language
67
Neutral language
25
Article tone
formal
Language
English
Language complexity
68
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
2
Source diversity
1
Affiliate links
no affiliate links